Filing Details
- Accession Number:
- 0001179110-21-010209
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-11-17 16:04:32
- Reporting Period:
- 2021-11-15
- Accepted Time:
- 2021-11-17 16:04:32
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1597264 | Blueprint Medicines Corp | BPMC | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1840110 | Becker L. Hewes | C/O Blueprint Medicines Corporation 45 Sidney Street Cambridge MA 02139 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-11-15 | 729 | $66.24 | 26,916 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-11-15 | 729 | $115.49 | 26,187 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2021-11-15 | 729 | $0.00 | 729 | $66.24 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
24,792 | 2030-06-01 | No | 4 | M | Direct |
Footnotes
- Effected pursuant to a trading plan adopted on August 13, 2021 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- This option was granted on June 1, 2020. This option vested with respect to 25% of the shares underlying the option on June 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter.